The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use announced on 9 November 2023 that it had recommended granting of marketing authorization for Rimmyrah (ranibizumab), a biosimilar that references ophthalmology drug, Lucentis.
EMA recommends approval of ranibizumab biosimilar Rimmyrah
Biosimilars/News | Posted 12/12/2023 0 Post your comment
Ranibizumab is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab. It inhibits angiogenesis (the formation of new blood vessels) by inhibiting vascular endothelial growth factor A (VEGF-A) [1].
Ranibizumab can be used to treat macular degeneration by inhibiting VEGF, which is responsible for the excessive formation of blood vessels in the retina leading to progressive loss of vision. The monoclonal antibody drug is indicated for the treatment of wet age-related macular degeneration (AMD), macular oedema, degenerative myopia and diabetes complications; all conditions of the eye causing vision loss [1].
The application for Rimmyrah was submitted by Qilu Pharma. The biosimilar is intended for the treatment of neovascular wet AMD, visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), and visual impairment due to choroidal neovascularisation (CNV).
Rimmyrah will be available as a 10 mg/mL solution for injection. EMA stipulates that this must be administered by an ophthalmologist experienced in administering intravitreal injections.
EMA has now approved four biosimilar versions of ranibizumab. Rimmyrah will join three other companies in competing in the European market, as shown in Table 1.
Table 1: Biosimilar ranibizumab approved in Europe |
Product name | Active substance | Therapeutic area | Authorization date |
Manufacturer/ Company name |
Byooviz | ranibizumab |
Degenerative myopia Diabetic retinopathy Macular oedema Wet macular degeneration |
18 Aug 2021 | Samsung Bioepis |
Ranivisio | ranibizumab |
Diabetes complications Diabetic retinopathy Macular oedema Wet macular degeneration |
25 Aug 2022 | Bioeq/Teva Pharma |
Rimmyrah | ranibizumab |
Choroidal neovascularisation Diabetic macular edema Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Proliferative diabetic retinopathy Wet age-related macular degeneration |
9 Nov 2023 | Qilu Pharma |
Ximluci | ranibizumab |
Diabetes complications Diabetic retinopathy Macular oedema Wet macular degeneration |
9 Nov 2022 | Stada Arzneimittel /Xbrane Biopharma |
Qilu is amongst the major pharmaceutical companies in China involved in the development of copy biologicals products, along with representative companies such as Henlius, Hisun, Innoventbio, Mabpharm [2].
Qilu has its bevacizumab copy biological, Ankeda, approved by China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), on 9 December 2023 [3]. Qilu initiated a phase III trial for denosumab copy biological in November 2019 [4].
Related articles
Canada approves ranibizumab biosimilar Byooviz
Generic lung cancer treatment now available in China
LATIN AMERICAN FORUM View the latest headline article: Genfar: La nueva marca de genéricos de Eurofarma en América Latina Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO Ver el último artículo de cabecera: Genfar: La nueva marca de genéricos de Eurofarma en América Latina !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. |
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of ranibizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-ranibizumab
2. GaBI Online - Generics and Biosimilars Initiative. Pharmaceutical companies in China manufacturing copy biologicals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from: www.gabionline.net/reports/pharmaceutical-companies-in-china-manufacturing-copy-biologicals
3. GaBI Online - Generics and Biosimilars Initiative. China approves bevacizumab copy biological Ankeda [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from: www.gabionline.net/biosimilars/news/china-approves-bevacizumab-copy-biological-ankeda
4. GaBI Online - Generics and Biosimilars Initiative. Qilu starts phase III trial for denosumab copy biological [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from: www.gabionline.net/biosimilars/news/Qilu-starts-phase-III-trial-for-denosumab-copy-biological
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.
Research
Long-term real-world safety experience of biosimilars confirms concept of biosimilarity
Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
General
Biosimilar medicines on the Pharmaceutical Benefits Scheme in Australia
SBR issues consensus on interchangeability of reference products and biosimilars
Comments (0)
Post your comment